Earli, Inc.
Work Here?
About Earli, Inc.
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$57.9M
Headquarters
San Francisco, California
Founded
2018
Overview
Company Does Not Provide H1B Sponsorship
Simplify's Take
What believers are saying
- Earli raised $60M to advance its cancer detection and treatment technology.
- Accenture's strategic investment indicates strong interest in Earli's innovative technology.
- The global cancer diagnostics market is projected to grow at a 7.2% CAGR until 2030.
What critics are saying
- Potential competition from startups like Grail could threaten Earli's market share.
- Regulatory hurdles in clinical trials may delay Earli's product launch.
- Reliance on synthetic biomarkers may face skepticism from the medical community.
What makes Earli, Inc. unique
- Earli engineers synthetic biomarkers for early cancer detection and treatment.
- The company focuses on lung cancer for its initial human clinical trials.
- Earli's technology forces cancer cells to produce detectable synthetic biomarkers.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$57.9M
Above
Industry Average
Funded Over
2 Rounds
Andreessen HorowitzIndustry standards
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -2%2 year growth
↑ 0%Earli, a startup founded by Cyriac Roeding, Dr. David Suhy, and the late Dr. Sanjiv Sam Gambhir, has raised $60 million to advance its cutting-edge cancer detection and treatment technology. The company engineers synthetic biomarkers within cancer cells, enabling earlier and more accurate detection and treatment. Following six years of research, Earli is preparing for human clinical trials, starting with lung cancer, and aims to expand its platform to other cancer types.
GLIN Impact Capital 有限責任事業組合のプレスリリース（2024年10月31日 12時10分）GLIN Impact Capital、がんの早期検出と即時治療につながる技術を開発する米Earliに出資
Accenture has made a strategic investment, through Accenture Ventures, in Earli Inc., a biotechnology company.
Earli, the company pioneering a new approach to cancer diagnostics by forcing cancer cells to produce synthetic biomarkers, announced today that Maggie Louie accepted the roll of Vice President of Biology.
When Shereen Asad joined Earli as its sixth employee in 2019, her job description didn’t exactly say anything about selling human blood samples.
Earli, Inc. is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Earli, Inc.
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$57.9M
Headquarters
San Francisco, California
Founded
2018
Earli, Inc. is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today